论文部分内容阅读
促红细胞生成素(erythropoietin,EPO),一种临床上主要用于慢性肾脏衰竭、人类免疫缺陷病毒感染、恶性肿瘤化疗后引起贫血的治疗及术后患者减少异种输血的替代治疗的药物,近年的研究发现其除了促造血作用外,还具有保护缺血再灌注损伤组织的作用,包括脑、肾、心脏组织等。EPO提供的心肌保护作用已经被证实与缺血预处理及缺血后处理操作提供的保护作用同样有效,且易于用于临床。现从EPO心肌保护的预适应、后适应等方面对促红细胞生成素心肌保护作用的治疗窗及相关机制进行综述。
Erythropoietin (EPO), a clinically used drug for the treatment of chronic kidney failure, human immunodeficiency virus infection, anemia caused by malignant tumor after chemotherapy, and alternative therapy to reduce heterotransfusion in postoperative patients, The study found that in addition to promoting hematopoietic function, but also has the protection of ischemia-reperfusion tissue injury, including brain, kidney, heart tissue. The cardioprotective effects provided by EPO have proven to be as effective as the protection afforded by ischemic preconditioning and ischemic postconditioning and are readily available in clinical settings. Now from EPO myocardial protection preconditioning, postconditioning and other aspects of erythropoietin myocardial protection of the therapeutic window and related mechanisms are reviewed.